AP 521

Drug Profile

AP 521

Latest Information Update: 03 Aug 2006

Price : $50

At a glance

  • Originator Asahi Kasei
  • Class Anxiolytics; Nootropics
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 1A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Cognition disorders

Most Recent Events

  • 03 Aug 2006 Discontinued - Phase-II for Anxiety disorders in Japan (PO)
  • 30 Jun 2005 Phase-II clinical trials in Anxiety disorders in Japan (PO)
  • 11 Apr 1995 Discontinued-Preclinical for Anxiety disorders in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top